Probiotic recolonisation therapy
The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli , anaerobic cocci, Ruminococcus, E. coli , Gemmiger, Desulfomonas, Peptostreptococcus , and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli , at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.
1. A method for treating a gastrointestinal disorder in a subject in need thereof, which method comprises orally administering to said subject an effective amount of a pharmaceutical composition comprising a viable non-pathogenic or attenuated pathogenic Clostridium ,a viable non-pathogenic or attenuated pathogenic Bacteroides , and a viable non-pathogenic or attenuated pathogenic Escherichia coli , wherein said pharmaceutical composition comprises between about 10 9 and about 10 11 viable microbes.
2. The method of claim 1 , wherein said gastrointestinal disorder is a Clostridium difficile infection.
3. The method of claim 1 , wherein said gastrointestinal disorder is a recurrent Clostridium difficile infection.
4. The method of claim 1 , wherein said gastrointestinal disorder is an inflammatory bowel disease.
5. The method of claim 1 , wherein said gastrointestinal disorder is ulcerative colitis.
6. The method of claim 1 , wherein said pharmaceutical composition is administered via a capsule adapted for enteric delivery.
7. The method of claim 1 , wherein said method further comprises administering one or more antibiotics prior to said administration of said pharmaceutical composition.
8. The method of claim 3 , wherein said method further comprises administering one or more antibiotics prior to said administration of said pharmaceutical composition.
9. A method for treating a gastrointestinal disorder in a subject in need thereof, which method comprises orally administering to said subject an effective amount of a pharmaceutical composition comprising a plurality of viable non-pathogenic or attenuated pathogenic spores of at least two Clostridium species, wherein said pharmaceutical composition comprises between about 10 9 and about 10 11 viable microbes.
10. The method of claim 9 , wherein said gastrointestinal disorder is a Clostridium difficile infection.
11. The method of claim 9 , wherein said gastrointestinal disorder is a recurrent Clostridium difficile infection.
12. The method of claim 9 , wherein said gastrointestinal disorder is an inflammatory bowel disease.
13. The method of claim 9 , wherein said gastrointestinal disorder is ulcerative colitis.
14. The method of claim 9 , wherein said method further comprises administering one or more antibiotics prior to said administration of said pharmaceutical composition.
15. The method of claim 11 , wherein said method further comprises administering one or more antibiotics prior to said administration of said pharmaceutical composition.
16. The method of claim 9 , wherein said pharmaceutical composition further comprises a viable non-pathogenic or attenuated pathogenic Bacteroides , a viable non-pathogenic or attenuated pathogenic E. coli , or both.
17. The method of claim 9 , wherein said method does not require the removal of a portion of said subject's existing enteric microflora via orthostatic lavage prior to said administration of said pharmaceutical composition.
18. The method of claim 1 , wherein said method does not require the removal of a portion of said subject's existing enteric microflora via orthostatic lavage prior to said administration of said pharmaceutical composition.
19. A method for treating a gastrointestinal disorder in a subject in need thereof, which method comprises orally administering to said subject an effective amount of a pharmaceutical composition comprising a viable non-pathogenic or attenuated pathogenic Clostridium , a viable non-pathogenic or attenuated pathogenic Bacteroides , and a viable non-pathogenic or attenuated pathogenic Escherichia. coli , wherein said pharmaceutical composition comprises between about 10 7 and about 10 9 viable microbes.
20. The method of claim 19 , wherein said gastrointestinal disorder is a Clostridium difficile infection.
21. The method of claim 19 , wherein said gastrointestinal disorder is a recurrent Clostridium difficile infection.
22. The method of claim 19 , wherein said gastrointestinal disorder is an inflammatory bowel disease.
23. The method of claim 19 , wherein said gastrointestinal disorder is ulcerative colitis.
24. The method of claim 19 , wherein said pharmaceutical composition is administered via a capsule adapted for enteric delivery.
25. The method of claim 19 , wherein said method further comprises administering one or more antibiotics prior to said administration of said pharmaceutical composition.
26. The method of claim 19 , wherein said method does not require the removal of a portion of said subject's existing enteric microflora via orthostatic lavage prior to said administration of said pharmaceutical composition.
27. A method for treating a gastrointestinal disorder in a subject in need thereof, which method comprises orally administering to said subject an effective amount of a pharmaceutical composition comprising a plurality of viable non-pathogenic or attenuated pathogenic spores of at least two Clostridium species, wherein said pharmaceutical composition comprises between about 10 7 and about 10 9 viable microbes.
28. The method of claim 27 , wherein said gastrointestinal disorder is a Clostridium difficile infection.
29. The method of claim 27 , wherein said gastrointestinal disorder is a recurrent Clostridium difficile infection.
30. The method of claim 27 , wherein said gastrointestinal disorder is an inflammatory bowel disease.
31. The method of claim 27 , wherein said gastrointestinal disorder is ulcerative colitis.
32. The method of claim 27 , wherein said pharmaceutical composition is administered via a capsule adapted for enteric delivery.
33. The method of claim 27 , wherein said method further comprises administering one or more antibiotics prior to said administration of said pharmaceutical composition.
34. The method of claim 27 , wherein said method does not require the removal of a portion of said subject's existing enteric microflora via orthostatic lavage prior to said administration of said pharmaceutical composition.